MedTech Terms
    The authoritative reference
    All terms

    Bottom-Up Market Sizing

    Building market size from procedure volumes × price × penetration.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Bottom-up sizing builds TAM from defensible inputs - incidence/prevalence, procedure volumes, addressable subset, average selling price, and realistic penetration curves - rather than top-down market percentages.
    What the regulation says
    While not directly a regulatory requirement, a well-substantiated bottom-up market sizing contributes to the overall business case and strategic planning reviewed by regulatory bodies like the FDA during pre-market submissions, especially for novel devices. It demonstrates a clear understanding of the target patient population and clinical need, which aligns with the safety and performance objectives of regulations such as the EU MDR Annex I, Sections 1 and 8. Detailed market understanding supports risk management activities as outlined in ISO 14971, allowing manufacturers to better identify potential harms related to device use in the intended population.

    What this means in practice

    Preferred by sophisticated MedTech investors. Inputs are sourced from registries (NCDR, STS), claims (HCUP, Medicare 5%/100%), and society reports.

    Examples

    • A manufacturer of a novel orthopedic implant uses patient registry data and surgical procedure codes (e.g., CPT codes) to estimate the addressable patient population and annual procedure volume.
    • A company developing a diagnostic test for a rare disease analyzes epidemiological data, insurance claims (e.g., ICD-10 codes), and expert clinician interviews to project the number of eligible patients and average diagnostic test prices.
    • A startup creating a digital therapeutic for chronic disease management calculates market size based on disease prevalence data from national health surveys, estimated patient engagement rates, and subscription pricing models.
    Common pitfalls
    • •Confusing revenue projections with market size, leading to an inflated sense of opportunity.
    • •Underestimating the burden of evidence required to support incidence and prevalence data, especially when extrapolating from limited sources.
    • •Failing to account for competitive landscapes and alternative treatments, which can significantly impact market penetration.
    • •Overlooking the dynamic nature of healthcare, including policy changes, technological advancements, and shifting clinical practices.
    • •Not adequately documenting the assumptions and data sources used, making the market size difficult to defend or update.

    Frequently asked questions

    While not a direct regulatory deliverable, robust bottom-up market sizing provides critical context for sections of regulatory submissions. It informs the justification for the device's intended use, target patient population, and clinical benefits, aligning with objectives of safety and effectiveness reviews by authorities like the FDA or under the EU MDR.
    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    AHRQ HCUP·1AdvaMed·1AHRMM·1
    1. 1
      HCUP
      Verified
      AHRQ HCUPhcup-us.ahrq.gov
    2. 2
      AdvaMed Code of Ethics
      Verified
      AdvaMedadvamed.org
    3. 3
      AHRMM - Healthcare Supply Chain
      Verified
      AHRMMahrmm.org

    Inline markers like [1] jump to the matching reference above.